Biopharma explores new obesity treatments beyond GLP-1s at ObesityWeek 2026
Audio narration · Coming soon
ObesityWeek 2026 will highlight emerging biopharmaceutical research focusing on the amylin pathway and novel therapies aimed at enhancing weight loss quality and patient adherence. This event marks a shift beyond the current emphasis on GLP-1 based treatments.
Originally published by gnews